Back to News
Market Impact: 0.2
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesPrivate Markets & Venture
Regeneron added REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody, to an alliance alongside a long-acting IL-4xIL-13 bispecific and two preclinical long-acting antibody programs. The expansion strengthens the alliance's respiratory/immunology pipeline, although the article provides no financial terms, clinical data, or commercialization timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
REGN0.35
More News
- Sanofi to pay Regeneron up to $8 billion to add new antibodies under Dupixent partnership
- Jefferies raises Regeneron stock price target to $930 on partnership
- Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
- Communiqué de presse : Sanofi et Regeneron élargissent leur Alliance mondiale avec plusieurs anticorps immunologiques de nouvelle génération à action prolongée
- Why the media’s whisper campaign about a Goldman Sachs change at the top is misleading gossip, at best
- SoftBank completes final phase of $30 billion investment in OpenAI